

Index

-
- action
 automatic vs. controlled performance, 103
 control of, 103
 inhibitory control deficits, 103
 lack of conscious control over, 103
 action tremor, 30
 activities of daily living (ADLs), 143
 activities of daily living (ADLs) score, 148
 Activity Scale for Kids (ASK), 205
 addictions, 88
 akinesia, 30, 40, 60, 62, 82, 162, 170
 PSP-pure akinesia with gait freezing (PAGF), 154
 alcohol
 intrathecal control of spasticity, 47
 alien hand syndrome, 103
 alpha-synuclein protein
 component of Lewy bodies, 140
 alpha-synuclein protein pathology 155
 multiple system atrophy, 155
 alprazolam, 30
 alternate and augmentative communication (AAC), 114, 118–119
 amantadine, 26, 158
 effects on levodopa-induced dyskinesia, 29
 Parkinson's disease medication, 29
 side effects, 29
 anal fissure, 44
 ankle-foot orthotics, 195
 use in Friedreich ataxia, 194–195
 anterior cervical rhizotomy, 49
 anticholinergic drugs, 39, 158
 use in Parkinson's disease, 26–27
 anticonvulsant drugs, 39
 anxiety, 88
 Anxiety Status Inventory, 99
 anxiety testing, 99
 apathy, 88
 Apathy Scale, 99
 aphasia, 98
 apomine, 145
 apomorphine, 7, 28
 apraxia, 25, 158
 aquatic physiotherapy, 193–194
 Ashworth scale, 50
 Asperger's disorder, 217, 218
 and intellectual disability, 224–225
 clinical description, 218–219
 compared with cerebral palsy, 222–223
 diagnostic criteria (DSM-IV-TR), 219
 early diagnosis of motor dysfunction, 227
 inter-professional management issues, 226
 management of motor dysfunction, 225–226, 227
 motor dysfunction, 221–222
 multidisciplinary interventions, 227
 neurobiology, 219–221
 aspiration pneumonia, 85
 assistive speech devices, 114
 ataxia, 75, 82, 153, 155, 157, 158
 See also cerebellar ataxia; Friedreich ataxia; spinocerebellar ataxia
 atenolol, 30
 athetosis, 111
 attention
 control of, 103
 attention deficit and disruptive behavior disorders (DSM-IV-TR), 217
 attention tests, 98
 atypical autism, 219
 autism, 217, 218
 and intellectual disability, 224–225
 clinical description, 218–219
 compared with cerebral palsy, 222–223
 diagnostic features (DSM-IV-TR), 219
 early diagnosis of motor dysfunction, 227
 inter-professional management issues, 226
 management of motor dysfunction, 225–226, 227
 motor dysfunction, 221–222
 multidisciplinary interventions, 227
 neurobiology, 219–221
 Autism Behavior Checklist, 223
 autism spectrum disorders (ASD), 219
 autonomic dysfunction, 5, 25, 37, 48, 133, 153–5, 158
 autosomal dominant inheritance 38
 Huntington's disease, 162
 baclofen
 intrathecal injections, 47–49, 194
 intrathecal pump, 39–40
 oral, 39, 194
 ballismus, 111
 basal ganglia 1
 actions of dopamine, 3
 anatomy in the normal state, 1–2
 associative loop, 1
 changes in activity in Parkinson's disease, 5
 classical amplitude model of physiology, 2–4
 direct pathway, 2–3
 effects of basal ganglia pathology, 1
 feedback circuits, 3
 functional loops, 1
 functional organization, 1, 2–4
 functions of the fronto-striatal circuits, 95–96
 indirect pathway, 2–3
 influences on thalamocortical activity, 2–3
 limbic loop, 1
 limitations of the classical amplitude model, 3–4
 motor loop, 1, 2
 oculomotor loop, 1
 orbitofrontal loop, 1
 pathology associated with movement disorders, 1
 physiology, 2–4
 procedural and skill learning, 104
 basal ganglia dysfunction
 movement disorders associated with, 94
 Beck Anxiety Inventory, 99
 Beck Depression Inventory, 99
 Behaviour Observation Scale
 Huntington, 83

Index

- behavioral disturbances with
 movement disorders, 88
 benzhexol, 26
 benzodiazepines, 39
 benztropine, 26, 39
 Berg Balance Scale, 168
 beta-blockers, 39
 biopsychosocial model, 126
 biological dimension of movement
 disorders, 126
 family dimension of movement
 disorders, 127
 psychological/emotional dimension
 of movement disorders, 126
 religious/spiritual/existential
 dimension of health challenges,
 127
 social/environmental dimension of
 health challenges, 127
 bladder dysfunction, 88–89
 blepharospasm, 40, 45
 botulinum toxin treatment, 45
 body-image disorders, 86
 BOLD magnetic resonance imaging
 (fMRI), 1
 Parkinson's disease, 7–8
 Boston Naming Test (BNT), 98, 116
 botulinum toxin, 44–45
 botulinum toxin A, 30
 botulinum toxin treatment
 blepharospasm, 45
 cervical dystonia, 39, 45
 dystonia, 174
 essential tremor, 46
 focal dystonias, 45–46
 for spasticity in Friedreich
 ataxia, 194
 hemifacial spasm, 45
 injection procedure for dystonias, 45
 injections, 40
 limb-task specific dystonias, 45–46
 Parkinson's disease dystonias, 46
 spastic dystonias, 46
 tremor, 46–47
 writer's cramp, 45–46
 bowel dysfunction, 88–89
 bradykinesia, 1, 82
 and BOLD fMRI imaging, 8
 and tremor, 30
 in Huntington's disease, 10–11, 162
 in parkinsonian syndromes, 152
 in Parkinson's disease, 7, 14
 movement strategy training, 60
 neuropsychology of, 103
 brain
 basal ganglia anatomy in the normal
 state, 1–2
 brain injury
 dystonias associated with, 45
 brainstem, 3, 20
 Brief Psychiatric Rating Scale, 99
 California Verbal Learning Test, 98
 Cambridge Neuropsychological
 Test Automated Battery
 (CANTAB), 99
 Canadian Occupational Performance
 Measure (COPM), 73, 205
 cabergoline, 27
 carbidopa, 28
 carbolic acid, 47
 care-givers
 support for, 89–90, 165–166
 casting to prevent contractures, 50
 catatonia, 25
 catechol-O-methyltransferase (COMT)
 inhibitors, 26
 combination with levodopa, 28
 entacapone, 28
 indications for use, 28
 Parkinson's disease medications, 28
 side effects, 28
 tolcapone, 28
 caudate nucleus, 1
 central nervous system, 39, 132,
 174, 188
 central sleep apnea, 159
 centromedian nucleus, 3
 cerebellar ataxia, 153
 cerebellar deficits 187
 cerebellar outflow tremor, 39
 cerebellar tremor, 30
 cerebellum, 3
 cerebral cortex, 1–3
 cerebral palsy, 40, 194, 195, 217, 218
 and intellectual disability,
 224–225
 compared with autism spectrum
 disorders, 222–223
 dystonia associated with, 45
 early diagnosis of motor
 dysfunction, 227
 importance of post-operative
 rehabilitation in SEMLS, 203
 indications for single-event
 multilevel surgery (SEMLS), 203
 inter-professional management
 issues, 226
 management of motor dysfunction,
 225–226, 227
 multidisciplinary interventions, 227
 progressive musculoskeletal
 pathology, 203
 rehabilitation principles, 134–136
 SEMLS procedure and rehabilitation
 process, 203–215
 cervical dystonia, 39, 40, 44, 45, 112
 botulinum toxin treatment, 39, 45
 common patterns, 45
 rehabilitation strategies, 176–177
 Childhood Autism Rating Scale, 223
 childhood disintegrative disorder, 219
 children with chronic movement
 disorders 136
 rehabilitation principles, 134–136
 Children's Assessment of Participation
 and Enjoyment (CAPE), 205
 cholinergic neurons, 5
 chorea, 25, 82, 111, 162
 causes, 32
 definition of chorea, 32
 dysarthria associated with, 111–112
 medical management, 32–33
 symptoms, 32
 Clinical Global Impression Scale, 99
 clinical utility of outcome measures, 237
 clinimetrics, 234–236
 responsiveness, 236
 validity, 236
 clock drawing test, 98
 clonazepam, 30
 clonidine, 194
 clozapine, 30
 cognitive effects in movement
 disorders, 94
 cognitive functions
 networks supporting, 95
 cognitive–linguistic disorders, 115
 assessment, 115–116
 management, 116
 communication assistance, 85
 alternate and augmentative
 communication (AAC), 114,
 118–119
 assistive speech devices, 114
 communication difficulties
 parkinsonian syndromes, 157
 Communication Effectiveness Survey
 (CES), 116
 Communication Function
 Classification System (CFCS), 223
 communication management
 Friedreich ataxia, 195
 See also language difficulties; speech
 difficulties.
 Communicative Abilities in Daily
 Living (CADL-2), 116
 community care
 parkinsonian syndromes, 158
 complex regional pain syndromes
 (CRPS)
 intrathecal baclofen therapy,
 48–49
 concurrent processing, 103
 constipation, 89
 constraint induced movement therapy
 (CIMT), 50

- construction tests, 98
 contractures, 49, 50, 188
 therapies, 193
 coprolalia, 112
 corticobasal degeneration, 152, 153
 neuropsychology, 101–102
 tau protein pathology, 155
 corticobasal syndrome
 clinical features, 155
 dysphagia management, 157–158
 gait and mobility rehabilitation
 issues, 156–157
 home and environmental
 assessment, 157
 medical management, 158–159
 multidisciplinary team care, 159
 nursing and community care, 158
 speech and communication
 difficulties, 157
 therapeutic strategies, 156
 upper and lower limb functional
 issues, 157
- dantrolene sodium, 194
 deep-brain stimulation (DBS), 5, 26, 31
 Parkinson's disease, 5, 7, 36–38
 side effects, 88
 Delis–Kaplan first letter and category
 verbal fluency test, 98
 dementia in Parkinson's disease
 assessment tools, 98–99
 dementia with Lewy bodies, 153
 depression, 88
 depression testing, 99
 desmopressin, 159
 detrusor overactivity, 44
 developmental coordination disorder
 (DSM-IV-TR), 217
 developmental disorders
 and motor dysfunction, 217
 approach to management of motor
 dysfunction, 226–227
 assessment of motor dysfunction, 218
 autism and Asperger's disorder, 218
 cerebral palsy, 218, 222–223
 classification, 217–218
 definition of motor dysfunction, 218
 early diagnosis of motor
 dysfunction, 227
 intellectual disability, 218, 224–225
 inter-professional management
 issues, 226
 management of motor dysfunction,
 218, 225–226, 227
 multidisciplinary interventions, 227
 nature of motor dysfunctions,
 226–227
 pervasive developmental
 disorders, 218
- Diagnostic and Statistical Manual of
 Mental Disorders, Fourth Edition,
 Text Revision. *See* DSM-IV-TR
 3,4-diaminopyridine, 25
 diazepam, 194
 dietician referral, 87–88
 differential diagnosis of movement
 disorders, 97
 domperidone, 28
 donepezil, 33
 Doors and People test, 98
 dopa-resistant dystonia, 30
 dopa-responsive dystonia, 3
 dopamine, 1
 actions in the basal ganglia, 3
 dopamine agonists, 7, 26
 advantages over levodopa, 27–28
 formulations, 28
 side effects, 28, 88
 use in Parkinson's disease, 27–28
 dopamine D₁ receptors, 3
 dopamine D₂ receptors, 3
 dopaminergic neurons, 2
 dorsal prefrontal cortex, 7
 drug-induced parkinsonism, 25, 153
 DSM-IV-TR
 classification of developmental
 disorders, 217–218
 diagnostic criteria for Asperger's
 disorder, 219
 diagnostic criteria for autism, 219
 DSM-5
 proposal for autism spectrum
 disorders category, 219
 duodopa, 28, 145
 dynorphin, 3
 dysarthria, 162
 assessment, 113–114
 hyperkinetic dysarthria, 111–113
 hypokinetic dysarthria, 110–111
 in Friedreich ataxia, 186
 treatment, 114
 types of, 110–113
 Dysarthria Impact Profile, 113
 dyskinesia, 1, 3, 5, 82
 See also levodopa-induced dyskinesia.
 dysphagia, 116–117, 162
 assessment, 117
 management, 117–118
 management in parkinsonian
 syndromes, 157–158
 dystonia, 25, 82, 111, 112, 162
 botulinum toxin injection
 procedure, 45
 botulinum toxin injections, 174
 causes, 11, 174
 classification, 45
 classification methods, 31
 clinical features, 174
 definition, 11, 31, 45
 dopa responsive, 11
 dystonic storm, 31
 functional neurosurgery, 39–40
 medical management, 31–32
 medical treatments, 174
 neurophysiological studies, 17–18
 neuropsychology, 102
 pathophysiology, 11, 17–18
 position-specific, 31
 prevalence, 174
 status dystonicus, 31
 surgical treatments, 174
 therapeutic approach, 31–32
 topographic classification, 31
 variation in severity, 31
 dystonia musculorum deformans
 rehabilitation strategies, 179–181
 dystonia rehabilitation, 174
 cervical dystonia, 176–177
 evidence for effectiveness,
 181–182
 generalized dystonia (dystonia
 musculorum deformans),
 179–181
 laryngeal dystonia (spasmodic
 dysphonia), 179
 musician's cramp, 178–179
 pathophysiological basis, 174–175
 principles, 175–176
 writer's cramp, 177–178
 dystonic storm, 31
 dystonic tremor, 39
 DYT-5 gene mutation, 11
- echolalia, 112
 ecosystemic perspective of social
 workers, 126
 Edinburgh Communication Functional
 Profile Revised, 116
 emotional control, 1
 encephalin, 164
 end-of-life care, 90
 enkephalin, 3
 entacapone, 28
 environmental assessment
 parkinsonian syndromes, 157
 Epworth Sleep Scale, 148
 equinovarus deformity, 187–188
 essential tremor, 112
 autosomal dominant inheritance, 38
 botulinum toxin treatment, 46
 functional neurosurgery, 38–39
 neuropsychology, 102
 treatment, 30–31
 executive function models, 95
 executive function tests, 98
 executive functions, 1
 executive overload, 103

Index

- exercise
 physiotherapy interventions, 58–59, 61–62
 extradural ramisectomy, 45
 extradural selective sectioning of dorsal rami, 49
 extrapyramidal bradykinesia, 152
 extrapyramidal rigidity, 154
 extrapyramidal system, 110
- fall prevention, 84–85
 physiotherapy interventions, 63–64
 familial tremor. *See* essential tremor
 family dimension of movement disorders, 127
 fatigue, 82
 Fatigue Severity Scale, 99
 FDG ([¹⁸F]-deoxyglucose) PET studies
 Parkinson's disease, 7
 FDOPA ([¹⁸F]-fluorodopa) PET studies
 Parkinson's disease, 5–6
 festination, 155
 flunarizine, 31
 focal dystonias, 44, 45, 112
 botulinum toxin treatment, 45–46
 freezing of gait, 25, 46, 82
 PSP-pure akinesia with gait freezing (PAGF), 154
 Freezing of Gait Scale, 83
 Friedreich ataxia
 age of onset, 185
 auditory pathway abnormality, 186–187
 capacity to participate in daily activities, 187
 cerebellar deficits, 187
 clinical features, 185
 cognitive effects, 187
 course of the disease, 185
 dysarthria, 186
 effects of poor foot alignment, 187–188
 equinovarus deformity, 187–188
 FXN gene mutations, 185
 hearing problems, 186–187
 impact on mobility, 185–186
 inheritance pattern, 185
 lower-limb spasticity and equinovarus deformity, 187–188
 management approaches, 185
 measures of functional capacity, 187
 neuropathology, 185
 prevalence, 185
 psychomotor dysfunction, 187
 speech and language effects, 186
 visual problems, 187
 Friedreich Ataxia Rating Scale (FARS), 187, 190
- Friedreich ataxia rehabilitation
 ankle-foot orthoses, 194–195
 aquatic physiotherapy, 193–194
 assessment, 189
 balance and posture assessment, 190
 balance training, 192
 cardiovascular exercises, 191–192
 communication management, 195
 compensation for impaired proprioception, 190
 coordination and strength assessment, 189–190
 functional communication assessment, 190
 gait assistive devices, 191
 gait re-education, 191
 hearing assessment, 190
 home environment adaptation, 195–196
 impact of sensory changes, 190
 improving core stability, 192
 maintenance of standing, 195
 management of scoliosis, 192–193
 motor activity assessment, 189–190
 multidisciplinary team involvement, 196
 pain assessment, 190
 practising transfers from one position to another, 191
 respiratory system considerations, 192
 spasticity assessment, 190
 spasticity management, 194
 speech assessment, 190
 strengthening exercises, 191–192
 stretching, 193
 studies, 188–189
 swallowing assessment, 190
 swallowing management, 195
 therapy outcome measures, 190
 upper-limb interventions, 193
 vision assessment, 190
 wheelchair prescription, 195
 Frontal Assessment Battery (FAB), 98
 fronto-striatal network functions, 95–96
 frontotemporal dementia
 syndromes, 155
 behavioral variant, 155
 in PSP patients, 155
 frontotemporal dementia with parkinsonism associated with chromosome-17, 153
 Functional Assessment of Communication Skills for Adults (ASHA FACS), 116
 functional imaging techniques, 1
 Functional Independence Measure (FIM), 83, 187, 188
 Functional Mobility Scale (FMS), 135
- functional MRI (fMRI) studies
 Huntington's disease, 11
 Parkinson's disease, 7–8
 functional neuroimaging
 findings in Parkinson's disease, 5–8
 use in neuropsychology, 94
 functional neurosurgery
 dystonia, 39–40
 essential tremor, 38–39
 future development of surgical options, 40
 Parkinson's disease, 36–38
 role in movement disorder management, 36
- GABA medium spiny neurons, 164
 GABAergic neurons
 striatum, 2–3, 8
 gabapentin, 30, 39
 gait and mobility rehabilitation
 parkinsonian syndromes, 156–157
 gait problems
 physiotherapy interventions, 61
 gamma knife thalamotomy, 31
 general practitioner, 145
 generalized dystonia
 rehabilitation strategies, 179–181
 genetic counseling, 86
 Huntington's disease, 86
 geriatrician, 145
 Gilles de la Tourette syndrome, 14, 112
 neurophysiological studies, 19–20
 pathophysiology, 19–20
 Gillette Gait Index (GGI), 203
 glial alpha-synuclein protein pathology
 multiple system atrophy, 155
 global rating of change scales, 237–240
 globus pallidus, 1
 globus pallidus externa, 1–3
 globus pallidus interna, 1–3
 goal attainment scaling (GAS), 240–241
 Gordon's 11 step model of functional health patterns, 83
 Graded Naming Test, 98
 Gross Motor Function Classification System (GMFCS), 135, 203, 223
 Gross Motor Function Measure (GMFM), 135
 ground reaction ankle-foot orthoses, 206–207
- H₂[¹⁵O] PET studies
 Parkinson's disease, 7
 habitual responses
 inhibitory control deficits, 103
 hallucinations, 88

- Hamilton Anxiety Rating Scale, 99
 Hamilton Depression Rating Scale, 99
 health related quality of life (HRQOL), 231–234
 hearing problems
 in Friedreich ataxia, 186–187
 hemidystonia, 40
 hemifacial spasm, 44–5
 hereditary spastic paraplegia
 rehabilitation principles, 134–136
 hereditary degenerative parkinsonism, 25
 Hoehn and Yahr scale, 236
 holistic management of movement disorders, 25
 Holmes tremor, 39
 home assessment
 parkinsonian syndromes, 157
 Hospital Anxiety and Depression Scale, 99
 Huntingtin protein, 162–164
 Huntington's disease, 153
 abnormal CAG sequence, 162
 age of onset, 162
 autosomal dominant inheritance, 162
 bradykinesia, 10–11
 cerebral glucose metabolism, 9–10
 cognitive deterioration, 33
 definition of chorea, 32
 description, 32–33
 diagnosis, 162
 functions of the social worker, 125–126
 genetic cause, 162
 genetic counseling, 86
 impairments associated with, 162
 influence of CAG repeat length, 9
 medical management, 32–33
 motor disorder management, 33
 mutated Huntingtin protein, 162–164
 neurobehavioral disorder management, 33
 neuropathology, 162–164
 neurophysiological studies, 18–19
 neuropsychology, 102
 pathophysiology, 8–11, 18–19
 prodromal symptoms, 162
 rate of disease progression, 9
 striatal degeneration, 8–11
 symptoms, 32–33
 Huntington's Disease Family Concerns and Strategies survey, 89
 Huntington's disease rehabilitation
 composition of the rehabilitation team, 166–167
 early stage of disease, 168–169
 evidence related to effective models for rehabilitation, 167
 family-centered approach, 165–166
 goals of rehabilitation, 170–171
 late stages of disease, 170
 mid stages of disease, 169–170
 prodromal stage, 167–168
 rehabilitation model, 164–165
 support for care-givers, 165–166
 treatments based on
 neuropathological knowledge, 162–164
 hyperhydrosis, 44
 hyperkinetic dysarthria, 111–113
 hyperkinetic movement disorders, 25
 hypersexuality, 88
 hypokinesia, 82, 162
 hypokinetic dysarthria, 110–111
 hypokinetic movement disorders, 25
 idiopathic dystonia, 174
 idiopathic focal dystonias, 45
 idiopathic Parkinson's disease, 139
 See also Parkinson's disease.
 impulse-control disorder, 88
 incoordination, 162
 inhibitory control deficits, 103
 intellectual disability, 217, 218
 and autism spectrum disorders, 224–225
 and cerebral palsy, 224–225
 early diagnosis of motor dysfunction, 227
 inter-professional management issues, 226
 management of motor dysfunction, 225–226, 227
 multidisciplinary interventions, 227
 intention tremor, 30
 International Classification of Functioning, Disability and Health (ICF), 57, 81, 113
 framework, 232–233
International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10, 1992), 217
 internet resources for people with movement disorders, 128–129
 intradural anterior rhizotomy, 45
 isometric tremor, 30
 kinetic tremor, 30
 language difficulties
 in Friedreich ataxia, 186
 laryngeal dystonia, 112
 rehabilitation strategies, 179
 learning disorders (DSM-IV-TR), 217
 Lee Silverman Voice Treatment (LSVT®), 114
 lentiform nucleus, 1
 levetiracetam, 31
 levodopa, 26–7
 combination with COMT inhibitors, 28
 dyskinesias associated with long-term use, 28
 formulations, 28
 Parkinson's disease medication, 28
 side effects, 28
 levodopa-induced dyskinesia, 16, 26, 36
 effects of amantadine, 29
 Lewy bodies
 alpha-synuclein protein component, 140
 in Parkinson's disease, 4, 5
 pathological distribution in Parkinson's disease, 139–140
 Lewy neurites
 in Parkinson's disease, 4, 5
 limb task specific dystonias
 botulinum toxin treatment, 45–46
 livedo reticularis, 29
 locus coeruleus, 3
 Manual Abilities Classification System (MACS), 223
 manual dexterity tests, 98
 Mattis Dementia Rating Scale (MDRS), 98, 101
 medical management of movement disorders
 chorea, 32–33
 dystonia, 31–32
 holistic management, 25
 Huntington's disease, 32–33
 multidisciplinary approach, 25
 parkinsonian syndromes, 158–159
 Parkinson's disease, 25–30
 symptomatic treatment, 25
 therapeutic approach, 25
 treatment of any underlying cause, 25
 tremor, 30–31
 medications
 management of side effects, 86
 Meige's syndrome, 39
 micrographia, 104, 154
 microvascular decompression of the spinal accessory nerve, 49
 Mini Mental State Examination (MMSE), 83, 98, 148
 Modified Barthel Index (MBI), 187
 monoamine oxidase-B (MAO-B) inhibitors, 26
 Montgomery Asberg Depression Rating Scale, 99

Index

- Montreal Cognitive Assessment (MoCA), 98
 mood assessment tools, 98
 mood disorder testing, 99
 motivations, 1
 motor cortex, 2
 motor loop of the basal ganglia, 1, 2
 motor-skills disorder (DSM-IV-TR), 217
 movement disorder care
 importance of outcome measurement, 231
 Movement Disorder Society, 26, 38, 98, 99, 128, 241
 movement rehabilitation, 49–50
 movement strategy training, 59–60, 62
 multidisciplinary team
 approach to medical management of movement disorders, 25
 movement disorder nurse, 81–91
 neuropsychologist, 94–105
 occupational therapist, 69–79
 physiotherapist, 55–65
 role in rehabilitation, 136–137
 skills and disciplines available, 145–147
 social worker, 124–129
 speech pathologist, 110–119
 multidisciplinary team care
 Friedreich ataxia, 196
 parkinsonian syndromes, 159
 speech and swallowing disorders, 85–86
 multiple sclerosis
 rehabilitation principles, 133–134
 tremor associated with, 39
 multiple system atrophy, 25, 152, 153
 advanced care, 156
 clinical features, 155–156
 diagnosis, 155
 dysphagia management, 157–158
 gait and mobility rehabilitation issues, 156–157
 glial alpha-synuclein protein pathology, 155
 home and environmental assessment, 157
 medical management, 158–159
 multidisciplinary team care, 159
 neuropsychology, 101
 nursing and community care, 158
 parkinsonian symptoms, 155
 prevalence, 155
 speech and communication difficulties, 157
 therapeutic strategies, 156
 upper and lower limb functional issues, 157
 multiple system degeneration, 25
 musician's cramp, 45
 rehabilitation strategies, 178–179
 myectomy of trapezius muscle, 45
 myoclonus, 25, 111
 impact on speech, 112
 nadolol, 30
 National Parkinson Foundation, 241
 neuroacanthocytosis, 153
 neuroferritinopathies, 153
 neuroleptic medications, 112
 neurologist, 145
 neurophysiological studies, 14
 dystonia, 17–18
 Gilles de la Tourette syndrome, 19–20
 Huntington's disease, 18–19
 Parkinson's disease, 14–17
 pathophysiological mechanisms of movement disorders, 20
 neuroplasticity and relearning capacity, 136
 Neuropsychiatric Inventory (NPI), 98, 99
 neuropsychological assessment
 commonly used tests and scales, 98–99
 differential diagnosis of movement disorders, 97
 impact of functional neurosurgery, 97
 level of daily functioning, 97–98
 longitudinal profile of movement disorders, 97
 practical considerations, 99–100
 reasons for, 96–98
 role in rehabilitation programs, 98
 neuropsychological principles
 application to movement disorder rehabilitation, 104–105
 neuropsychology
 definition, 94–95
 executive function models, 95
 functional neuroimaging, 94
 functions of the fronto-striatal network, 95–96
 networks supporting cognitive functions, 95
 transcranial magnetic stimulation (TMS), 94–95
 neuropsychology of movement disorders, 100
 automatic vs. controlled performance of action, 103
 basal ganglia dysfunction, 94
 bradykinesia, 103
 cognitive and motor functional effects, 94
 concurrent processing difficulty, 103
 consequences of executive overload, 103
 corticobasal degeneration, 101–102
 deficits in inhibitory control, 103
 doing two things at once, 103
 dystonia, 102
 essential tremor, 102
 higher motor control in movement disorders, 102–104
 Huntington's disease, 102
 internal vs. external control of attention and action, 103
 lack of conscious control over action, 103
 multiple system atrophy, 101
 non-motor symptoms, 94
 Parkinson's disease, 100–101
 primary dystonia, 102
 procedural learning, 104
 progressive supranuclear palsy, 101
 similarities across conditions, 102
 skill learning, 104
 speed of processing and motor preparation, 103
 temporal processing, 103
 neurorehabilitation, 131
 Neurosensory Centre Comprehensive Examination for Aphasia (NCCEA), 116
 neurotransmitters, 100, 158
 dopamine, 27
 nigrostriatal degeneration in Parkinson's disease, 4
 nigrostriatal pathway, 2
 nimodipine, 30
 NMDA glutamate receptor antagonist 29
 amantadine, 29
 nocturia, 87
 noradrenaline, 159
 noradrenergic neurons, 5
 normal pressure hydrocephalus, 25, 153
 nucleus accumbens, 1
 nursing
 aims of movement disorder nursing, 82–83
 assessing depression and anxiety, 88
 assessing sexual dysfunction, 88
 assisting communication, 85
 behavioral disturbances with movement disorders, 88
 clinical research and the nursing role, 90
 education and health promotion, 86
 encouraging physical activities, 84
 fall prevention, 84–85
 Gordon's 11 step model of functional health patterns, 83

- helping patients cope with bladder and bowel dysfunction, 88–89
 importance in movement disorder care, 91
 interventions during the course of the disease, 83–85
 interventions in later stages, 85
 managing medication side effects, 86
 medication management, 86
 monitoring nutrition, 87–88
 movement disorder assessment tools, 83
 palliative care, 90
 parkinsonian syndromes, 158
 patient assessment and observation, 83
 prevention of secondary complications, 86–88
 promoting adaptation to new roles, 85–86
 promoting independence and self-care, 85–86
 promotion of quality of life, 83–85
 range of impairments in people with movement disorders, 82
 rehabilitation nursing, 81
 role in the multidisciplinary team, 82
 role of the movement disorder nurse, 81–82
 supporting care-givers, 89–90
 supporting movement strategies, 84
 swallowing difficulty management, 85–86
 nutrition, 87–88
- obsessive-compulsive disorders, 88
 obstructive sleep apnea, 159
 occupational therapist, 72, 85
 occupational therapy
 evidence for effectiveness in movement disorders, 69–71
 goals and values, 69
 goals for different movement disorders, 77
 importance of contextual information, 72
 patient-centered approach, 69, 71–72
 research challenges, 70–71
 research studies, 69–71
 role in rehabilitation of people with movement disorders, 77–79
 types of interventions used, 69
 underpinning principles, 71–72
 use of accessible terminology and language, 72
 occupational therapy process framework, 72–77
- activity analysis, 74–75
 assessment phase, 72–75
 attitude level intervention, 77
 core components, 72
 goal setting, 73–74
 knowledge level intervention, 76–77
 levels of intervention, 72
 referral on to other services, 75
 roles of the occupational therapist, 72
 skill level intervention, 76
 treatment phase, 72–73, 75–77
- off painful dystonia, 46
 on-off effect of medication, 148
 on-off effect with levodopa, 28
 orofacial spasms, 39
 orolingual-mandibular dystonia, 112
 oromandibular apraxia, 158
 orthoses, 206–207
 use in Friedreich ataxia, 194–195
 orthostatic hypertension, 158–159
 orthostatic hypotension, 85, 87
 orthostatic tremor, 39
 outcome measures
 and the ICF model, 232–233
 choosing what to measure, 232–234
 clinical utility, 237
 clinimetrics, 234–236
 common measures used for people with movement disorders, 237
 definition, 231
 feasibility of use, 237
 Friedreich ataxia therapies, 190
 health related quality of life (HRQOL), 231–234
 importance in movement disorder care, 231
 interpretability, 237
 non-standard measurement tools, 237–241
 physiotherapy interventions, 64–65
 practical considerations, 237
 reasons for carrying out measurement, 231–232
 reliability of measurements, 234–236
 resources available, 241
 responsiveness, 236
 role in evidence-based practice, 231
 selection case scenario, 241–240
 selection criteria, 231–234
 validity of measurements, 236
- outreach service, 148
 Oxford Geriatric Depression Scale, 88
- paced auditory serial addition test, 98
 pain, 82
 pain management
 effects of botulinum toxin, 44
 surgical interventions, 36
 palatopharyngolaryngeal myoclonus, 112
- palilalia, 112
 palliative care, 90
 pallidotomy, 3, 5, 7
 pantothenate kinase-associated neurodegeneration (PKAN), 48
 paresthesia, 47, 48
 parafascicular nucleus, 3
 paresis, 82
 Parkinson Neuropsychometric Dementia Assessment (PANDA), 99
 parkinsonian syndromes
 approach to rehabilitation, 152
 dysphagia management, 157–158
 gait and mobility rehabilitation issues, 156–157
 home and environmental assessment, 157
 list of conditions included, 152–153
 medical management, 158–159
 multidisciplinary team care, 159
 nursing and community care, 158
 speech and communication difficulties, 157
 therapeutic strategies, 156
 upper and lower limb functional issues, 157
 See also specific syndromes.
- parkinsonism
 classification of types, 25
 parkinsonism dementia complex of Guam, 153
 Parkinson's disease, 1
 botulinum toxin treatment of dystonias, 46
 changes in basal ganglia activity, 5
 deep brain stimulation (DBS), 5, 36–38
 description, 25
 dystonia associated with, 45
 effects of basal ganglia pathology, 1
 functional neuroimaging findings, 5–8
 functional neurosurgery, 36–38
 functions of the social worker, 125
 hypokinetic dysarthria, 110–111
 Lewy bodies, 4, 5
 Lewy neurites, 4, 5
 medical management, 25–30
 medical treatment algorithm, 29–30
 motor symptoms, 14
 neuropsychological studies, 14–17
 neuropsychology, 100–101
 nigrostriatal degeneration, 4
 pathological distribution of Lewy bodies, 139–140
 pathophysiology, 4–8, 14–17
 primary parkinsonism, 25
 search for neuroprotective agents, 25
 search for neurorestorative treatment, 26

Index

- Parkinson's disease (cont.)
 staging system, 4
 strategies to delay or manage motor complications, 26
 symptomatic treatment, 25–26
 symptoms, 25
 tests for dementia, 98–99
 therapeutic strategies, 25–26
- Parkinson's Disease Cognitive Rating Scale (PD-CRS), 99
- Parkinson's Disease Functional Scale (PDFS 16), 147
- Parkinson's disease medications
 amantadine, 29
 anticholinergics, 26–27
 catechol-O-methyltransferase (COMT) inhibitors, 28
 choice of medication, 26
 dopamine agonists, 27–28
 entacapone, 28
 levodopa, 28
 monoamine oxidase-B (MAO-B) inhibitors, 26
 rasagiline, 26
 selegiline, 26
 tolcapone, 28
- Parkinson's disease rehabilitation
 complexity of Parkinson's disease pathology, 139–140
 integration into multidisciplinary team care, 145–147
 medical care model, 143–145
 multidisciplinary team approach, 150
 multidisciplinary team care model, 139
 organizational structure of contact points, 147–148
 promoting self-management, 148–150
 theoretical basis, 140–143
- Parkinson's Disease Sleep Scale (PDSS), 148
- Parkinson's Fatigue Scale, 99
- Parkinson's Quality of Life Scale (PDQ 39), 83, 147, 148
- pathological gambling, 88
- pediatric neuro-disability medical specialty, 217–218
- pedunculopontine DBS, 38
- pedunculopontine nucleus, 3, 15
- pergolide, 28
- peripheral surgical treatments, 49
- peripheral therapies
 botulinum toxin treatment, 45–47
 indications for, 44
 intrathecal alcohol injection, 47
 intrathecal baclofen therapy, 47–49
 movement rehabilitation, 49–50
 phenolization of nerves, 47
 physiotherapy, 49–50
 types of, 44
- pervasive developmental disorder not otherwise specified (PDD-NOS), 219
- pervasive developmental disorders (PDDs), 217, 218
See also Asperger's disorder; autism.
- pes cavus, 188
- PET (positron emission tomography), 1
- PET imaging studies
 Parkinson's disease, 5–7
- PET imaging techniques
 findings in Huntington's disease, 8–11
- pet therapy, 90
- phenolization of peripheral nerves, 47
- Physical Performance Test, 167
- physical therapy, 49–50
- physiotherapist, 85
 role in movement disorder rehabilitation, 55–57
- physiotherapy
 clinical framework for movement disorder management, 57–58
 exercise interventions, 58–59, 61–62
 fall-prevention interventions, 63–64
 gait interventions, 61
 measuring outcomes, 64–65
 movement strategy training, 59–60, 62
 postural control interventions, 62–63
 problem-orientated approach, 61–64
 role in movement disorder management, 49–50, 55
 transfer movement strategies, 64
 upper limb dysfunction interventions, 64
- picture naming tasks, 98
- position-specific dystonia, 31
- position-specific postural tremor, 30
- Positive and Negative Syndrome Scale, 99
- positron emission tomography. *See* PET
- posteroventral pallidotomy, 39
- post-hypoxic parkinsonism, 153
- post-stroke parkinsonism, 153
- post-stroke tremor, 39
- post-traumatic parkinsonism, 152, 153
- post-traumatic tremor, 39
- postural control
 physiotherapy interventions, 62–63
 postural instability, 82, 162
 postural tremor, 30
- predominant apraxia of speech, 155
- pregabalin, 30
- prepotent responses
 inhibitory control deficits, 103
- primary dystonia
 functional neurosurgery, 39–40
 neuropsychology, 102
- primary parkinsonism, 25
- primary somatosensory cortex, 2
- primidone, 30, 39
- procedural learning, 104
- processing speed tests, 98
- progressive non-fluent aphasia, 155
- progressive supranuclear gaze palsy, 25
- progressive supranuclear palsy (PSP), 152, 153
 clinical subtypes, 152
 diagnosis, 152
 dysphagia management, 157–158
 gait and mobility rehabilitation issues, 156–157
 home and environmental assessment, 157
 medical management, 158–159
 multidisciplinary team care, 159
 neuropsychology, 101
 nursing and community care, 158
 prevalence, 152
 Richardson's syndrome (PSP-RS), 152–153
 speech and communication difficulties, 157
 tau protein pathology, 152
 therapeutic strategies, 156
 upper- and lower-limb functional issues, 157
 with features of frontotemporal dementia, 155
- propranolol, 30, 39
- PSP-corticobasal syndrome (PSP-CBS), 152
- PSP-parkinsonism (PSP-P), 152
 clinical features, 153–154
 diagnosis, 154
- PSP-progressive non-fluent aphasia (PNFA), 152
- PSP-pure akinesia with gait freezing (PAGF), 152
 clinical features, 154
 diagnosis, 154
- PSP-RS. *See* Richardson's syndrome
- psychiatric testing, 99
- psychiatrist, 145
- psychological/emotional dimension of movement disorders, 126
- psychomotor dysfunction
 Friedreich ataxia, 187
- psychosis, 27, 33, 99
- Purdue Pegboard, 98
- Purkinje cells, 220
- putamen, 1
- quality of life (QOL), 233–234
- range of motion, 58, 61, 63, 64, 170, 176, 194, 215

- raphe nuclei, 3
 rasagiline, 26
 Recognition Memory for Faces test, 98
 reflex sympathetic dystrophy, 48
 rehabilitation
 cerebral palsy, 134–136
 children with chronic movement disorders, 134–136
 hereditary spastic paraplegia, 134–136
 multiple sclerosis, 133–134
 Parkinson's disease, 139–150
 traumatic brain injury, 131–133
 Rehabilitation Measures Database, 241
 rehabilitation principles, 131
 functions of the multidisciplinary team, 136–137
 neuroplasticity and relearning capacity, 136
 programs tailored to individual needs, 136–137
 variability of clinical presentation, 136–137
 reliability of outcome measurements, 234–236
 religious/spiritual/existential dimension of health challenges, 127
 REM sleep disorders, 88
 resources for people with movement disorders, 128–129
 responsiveness of outcome measures, 236
 rest tremor, 30
 resting tremor, 46
 Rett's disorder, 217, 219
 reward-related activities, 1
 Richardson's syndrome (PSP-RS), 152–3
 rigidity, 1, 14, 25, 82, 152, 162
 Ropinirole, 27
 rotigotine, 28

 Scales for Outcomes of Parkinson's Disease – Cognition (SCOPA-COG), 99
 Schedule for Assessment of Positive Symptoms, 99
 secondary dystonia
 functional neurosurgery, 39–40
 secondary parkinsonism, 25
 selective dorsal rhizotomy, 49
 selegiline, 26
 self-help groups, 128–129
 sensory impairment, 82
 serotonergic neurons, 5
 sexual dysfunction, 88, 159
 sialorrhea (excessive drooling), 85, 117, 158
 sinemet, 145

 single event multilevel surgery (SEMLS)
 anesthesia, 207–208
 analgesia, 207–208
 assistive devices required after surgery, 205–207
 consent issues, 205
 implant removal and fine tuning, 214
 importance of postoperative rehabilitation, 203
 indications in cerebral palsy patients, 203
 inpatient stay, 207–210
 post-operative 12 month gait laboratory reassessment, 213–214
 post-operative equipment, 208–209
 post-operative months 6–12, 213
 post-operative positioning, 208–209
 post-operative rehabilitation, 208–209
 post-operative weeks 1–3, 210–211
 post-operative weeks 3–6, 211
 post-operative weeks 6–12, 212–213
 post-operative weeks 12–24, 664–65
 pre-operative baseline function assessment, 205
 pre-operative diagnostic review, 205
 pre-operative planning, 204–207
 preparation for discharge, 209–210
 rehabilitation stages, 203
 what to expect in the second post-operative year, 215
 single photon emission computed tomography
 6-meter walk test, 82
 skill learning, 104
 sleep disorders, 88
 social justice, 127
 social work referral, 86
 social worker
 biological dimension of movement disorders, 126
 biopsychosocial model, 126
 building connections to resources, 128–129
 commitment to social justice, 127
 ecosystemic perspective, 126
 family dimension of movement disorders, 127
 links with self-help groups, 128–129
 Mildred case study (Parkinson's disease), 128
 partnership with the client, 127
 peer support, 127
 psychological/emotional dimension of movement disorders, 126
 religious/spiritual/existential dimension of health challenges, 127
 role during the course of a disease, 128
 role in supporting people with movement disorders, 124–125
 role in the multidisciplinary team, 124–125, 129
 social/environmental dimension of health challenges, 127
 work with people with Huntington's disease, 125–126
 work with people with Parkinson's disease, 125
 social/environmental dimension of health challenges, 127
 sotalol, 30
 spasmodic dysphonia, 39, 40, 44, 45, 112
 rehabilitation strategies, 179
 spasmodic torticollis, 39, 45
 spastic dystonia
 botulinum toxin treatment, 46
 spastic dystonias, 45
 Spastic Paraplegia Rating Scale (SPRS), 135
 spasticity, 82
 and equinovarus deformity, 187–188
 lower limbs, 187–188
 spasticity management
 intrathecal alcohol, 47
 phenolization of peripheral nerves, 47
 surgical procedures, 49
 SPECT (single-photon emission computed tomography), 1
 SPECT imaging
 Huntington's disease, 8–10
 Parkinson's disease, 5–6
 speech difficulties. *See* SPECT
 in Friedreich ataxia, 186
 parkinsonian syndromes, 157
 speech disorders
 dysarthria, 110–113
 hyperkinetic dysarthria, 111–113
 hypokinetic dysarthria, 110–111
 speech pathologist, 85, 86
 approach to movement disorder rehabilitation, 110
 assistive speech devices, 114
 cognitive–linguistic disorders, 115–116
 dysarthria assessment, 113–114
 dysarthria treatment, 114
 dysphagia in movement disorder patients, 116–118
 hyperkinetic dysarthria, 111–113
 hypokinetic dysarthria, 110–111
 role in movement disorder rehabilitation, 119
 swallowing disorders, 116–118
 use of technologies in service delivery, 118–119
 speech therapist referral, 85

Index

- Spielberger Stait-Trait Anxiety Inventory, 99
 spinal cord, 19, 20, 47–9, 133, 135, 185, 188
 spinal-cord injury, 192, 195
 spinocerebellar ataxia, 25, 153
 sport, 215, 222
 status dystonicus, 31
 Steele–Richardson–Olszewski syndrome, 152
 stereotactic surgery, 5
 stigma and movement disorders, 86
 striatal GABAergic medium spiny neurons, 2–3, 8
 striatum, 1–3
 degeneration in Huntington's disease, 8–11
 stroke
 dystonias associated with, 45
 Stroop test, 98, 100
 substance P, 3
 substantia nigra, 1–2
 substantia nigra pars compacta, 14
 substantia nigra pars reticulata, 14
 subthalamic nucleus, 1–3, 14
 Sudek's atrophy, 48
 supervisory attention system (SAS)
 concept, 95
 supplementary motor area, 2, 7
 surgical interventions
 role in movement disorder management, 36
 See also functional neurosurgery; peripheral surgery; single event multilevel surgery (SEMLS).
 swallowing disorders, 116–117
 assessment, 117
 management, 117–118
 swallowing management and secretion management, 85–86
 Friedreich ataxia, 195
 synuclein immunocytochemistry, 4

 tai chi, 134
 Tardieu Scale, 190
 tardive dyskinesia, 111, 112
 tardive dystonia, 40
 task-specific dystonias
 botulinum toxin treatment, 45–46
 task-specific kinetic tremor, 30
 tau protein pathology
 corticobasal degeneration, 155
 progressive supranuclear palsy, 152
 technology
 role in speech disorder rehabilitation, 118–119
 telerehabilitation, 118
 temporal processing, 103
 Test of Language Competence – Expanded Edition (TLCE-E), 116
 tetrabenazine, 33, 174
 thalamotomy, 31, 39
 thalamus, 1, 2, 3
 The Word Test – Revised (TWT-R), 116
 thermal regulation disturbance, 87
 tic disorders, 82, 111, 112
 DSM-IV-TR criteria, 217
 tics, 25
 Timed Up and Go test (TUG), 83, 236
 Tinneti Scale, 167
 toe clawing, 188
 tolcapone, 28
 topiramate, 30, 39
 torsion dystonia, 48
 Tower of London test, 7, 98, 100
 Trail Making test, 98
 transcranial magnetic stimulation (TMS) 95
 use in neuropsychology, 94–95
 transcranial magnetic stimulation (TMS) studies
 dystonia, 17–18
 Gilles de la Tourette syndrome, 19
 Huntington's disease, 19
 Parkinson's disease, 15–16
 transfer movements
 physiotherapy interventions, 64
 traumatic brain injury, 194
 rehabilitation principles, 131–133
 tremor, 25, 82, 111
 action tremor, 30
 botulinum toxin treatment, 46–47
 cerebellar tremor, 30
 classification, 30
 clinical evaluation, 30
 definition, 30
 essential tremor treatment, 30–31
 in Parkinson's disease, 14
 intention tremor, 30
 isometric tremor, 30
 kinetic tremor, 30
 medical management, 30–31
 position-specific postural tremor, 30
 postural tremor, 30
 rest tremor, 30
 task-specific kinetic tremor, 30
 treatment, 30–31
 trihexyphenidyl, 26, 39

 Unified Huntington's Disease Rating Scale (UHDRS), 113, 168
 Unified Parkinson's Disease Rating Scale (UPDRS), 6, 83, 147, 148, 236
 upper- and lower-limb function 157
 parkinsonian syndromes, 157
 upper-limb dysfunction
 physiotherapy interventions, 64
 urinary-tract infections, 89
 utilization behavior, 103

 validity of outcome measurements, 236
 vascular parkinsonism, 25, 152, 153
 dysphagia management, 157–158
 gait and mobility rehabilitation issues, 156–157
 home and environmental assessment, 157
 medical management, 158–159
 multidisciplinary team care, 159
 nursing and community care, 158
 speech and communication difficulties, 157
 therapeutic strategies, 156
 upper- and lower-limb functional issues, 157
 verbal fluency tests, 100
 vestibular dysfunction, 82
 visual problems
 in Friedreich ataxia, 187
 visuo-spatial function tests, 98
 vocal tics, 112
 voice tremor, 113

 wearing-off effect with levodopa, 28
 Wechsler Adult Intelligence Scales (WAIS-III or IV), 98
 WEMOVE web page, 241
 Western Aphasia Battery – Revised (WAB-R), 116
 Wiig-Semel Test of Linguistic Concepts (WSTLC), 116
 Wilson's disease, 25, 153
 Wisconsin card sorting test, 98, 100
 working memory model (Baddeley), 95
 working memory tests, 98
 writer's cramp, 39, 45
 botulinum toxin treatment, 45–46
 rehabilitation strategies, 177–178

 yoga, 134

 zonisamide, 30
 Zung Self-rating Anxiety Scale, 99